A. It is available in a combination tablet with simvastatin B. It should be used in caution in patients with hypothyroidism C. It should be taken as one tablet by mouth once daily D. It is FDA-approved to reduce triglycerides in patients with elevated levels E. Unsure

A. A 64-year-old male with no past cardiovascular history and an LDL of 79 mg/dL and low ASCVD risk B. A 58-year-old female with a prior myocardial infarction on statin therapy with an LDL of 64 mg/dL C. A 79-year-old male with Type II diabetes on a moderate intensity statin with an LDL of 115 mg/dL D. A 56-year-old female with heterozygous familial hypercholesterolemia on maximally tolerated statin and ezetimibe therapy with an LDL of 110 mg/dL E. Unsure

A. Icosapent ethyl is a combination EPA and DHA fish oil product B. Icosapent ethyl reduces cardiovascular outcomes regardless of LDL levels in high risk patients C. Despite patent challenges, icosapent ethyl remains brand name only D. The cardiovascular protective effects of icosapent ethyl can be extrapolated to other fish oil products E. Unsure

A. A 64-year-old male with no past cardiovascular history and an LDL of 79 mg/dL and low ASCVD risk. B. A 58-year-old female with a prior myocardial infarction on high-intensity statin therapy with an LDL of 64 mg/dL C. A 56-year-old female with heterozygous familial hypercholesterolemia on maximally tolerated statin and ezetimibe therapy with an LDL of 110 mg/dL D. A 23-year-old male with a family history of high LDL and an untreated LDL of 153 mg/dL E. Unsure

A. Evinacumab targets PCSK9, while inclisiran is an angiopoietin-like protein 3 inhibitor B. Evinacumab targets PCSK9, while inclisiran is an ATP citrate lyase inhibitor C. Evinacumab is an angiopoietin-like protein 3 inhibitor, while inclisiran targets PCSK9 D. Evinacumab is an ATP citrate lyase inhibitor, while inclisiran targets PCSK9 E. Unsure